Search research articles
Contact Us
Filters
Showing results (151-160 of 167) with videos related to
Page
of 17
Sort By:
Blood Advances
|
September 21, 2021
Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies
Matthew S Davids, Owen A O'Connor, Wojciech Jurczak, et al.
Journal for Immunotherapy of Cancer
|
December 21, 2025
TGF-βRII/IL-15 immunotherapeutic complex targets exhausted CD8<sup>+</sup> T-cell subsets in lymph nodes and tumors
Varghese K George, Hing C Wong, Martin Felices, et al.
The Lancet. Oncology
|
December 16, 2019
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials
Alexander Drilon, Salvatore Siena, Rafal Dziadziuszko, et al.
The Lancet. Haematology
|
July 21, 2024
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study
William G Wierda, Nirav N Shah, Chan Y Cheah, et al.
The New England Journal of Medicine
|
July 5, 2023
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia
Anthony R Mato, Jennifer A Woyach, Jennifer R Brown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 9, 2025
Single-Agent Divarasib in Patients With <i>KRAS G12C</i>-Positive Non-Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study
Adrian G Sacher, Wilson H Miller, Manish R Patel, et al.
Nature Medicine
|
December 5, 2023
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial
Jayesh Desai, Guzman Alonso, Se Hyun Kim, et al.
Haematologica
|
October 4, 2024
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial
Nirav N Shah, Michael Wang, Lindsey E Roeker, et al.
The Lancet. Haematology
|
May 2, 2026
Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial
M Lia Palomba, Manish R Patel, Toby A Eyre, et al.
Nature
|
April 12, 2019
No detection of methane on Mars from early ExoMars Trace Gas Orbiter observations
Oleg Korablev, Ann Carine Vandaele, Franck Montmessin, et al.
Page
of 17
Search research articles
Search
Showing results (151-160 of 167) with videos related to
Sort By:
Page
of 17
Blood Advances
|
September 21, 2021
Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies
Matthew S Davids, Owen A O'Connor, Wojciech Jurczak, et al.
Journal for Immunotherapy of Cancer
|
December 21, 2025
TGF-βRII/IL-15 immunotherapeutic complex targets exhausted CD8<sup>+</sup> T-cell subsets in lymph nodes and tumors
Varghese K George, Hing C Wong, Martin Felices, et al.
The Lancet. Oncology
|
December 16, 2019
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials
Alexander Drilon, Salvatore Siena, Rafal Dziadziuszko, et al.
The Lancet. Haematology
|
July 21, 2024
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study
William G Wierda, Nirav N Shah, Chan Y Cheah, et al.
The New England Journal of Medicine
|
July 5, 2023
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia
Anthony R Mato, Jennifer A Woyach, Jennifer R Brown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 9, 2025
Single-Agent Divarasib in Patients With <i>KRAS G12C</i>-Positive Non-Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study
Adrian G Sacher, Wilson H Miller, Manish R Patel, et al.
Nature Medicine
|
December 5, 2023
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial
Jayesh Desai, Guzman Alonso, Se Hyun Kim, et al.
Haematologica
|
October 4, 2024
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial
Nirav N Shah, Michael Wang, Lindsey E Roeker, et al.
The Lancet. Haematology
|
May 2, 2026
Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial
M Lia Palomba, Manish R Patel, Toby A Eyre, et al.
Nature
|
April 12, 2019
No detection of methane on Mars from early ExoMars Trace Gas Orbiter observations
Oleg Korablev, Ann Carine Vandaele, Franck Montmessin, et al.
Page
of 17